Supernus Announces Third Quarter 2020 Financial Results
ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the third quarter of 2020 and associated Company developments.
“During the first nine months of 2020, we delivered strong product sales growth, diversified our revenue base and enhanced our long term growth with two corporate transactions” said Jack Khattar, President and CEO of Supernus. “Our employees have been hard at work in anticipation of the launch of SPN-812. Based on the efficacy and safety demonstrated in its clinical program, SPN-812 can potentially offer an important new option in the treatment of ADHD.”
Third quarter 2020 net product sales were $152.1 million, 52% higher than the same period in 2019, driven by the addition of $40.9 million of net product sales from the acquired commercial products and $11.2 million in net product sales growth from Trokendi XR and Oxtellar XR.
|Net Product Sales
($ in millions)
|Q3 2020||Q3 2019||Change %|
|Trokendi XR||$||82.9||$||77.3||7 %|
|Oxtellar XR||28.3||22.7||25 %|
(1) Fluctuation in terms of percentage change is not meaningful.
Product Pipeline Update
SPN-812 - Novel non-stimulant for the treatment of ADHD in children and adults
- The Company continues to prepare for the commercial launch of SPN-812, which is expected in January 2021, if approved by the FDA. The New Drug Application (NDA) Prescription Drug User Fee Act (PDUFA) target action date is November 8, 2020.
- The Company completed enrollment in the SPN-812 Phase III trial in adult patients with ADHD. Topline data from the trial is expected in the first quarter of 2021.
SPN-830 (Apomorphine infusion pump) - Continuous treatment of motor fluctuations (“on-off” episodes) in PD
- NDA was submitted to the U.S. Food and Drug Administration (FDA) in September 2020 for the continuous treatment of "on-off" episodes in adults with Parkinson's disease (PD) whose motor control is unsatisfactory with oral levodopa and at least one other noninvasive PD therapy.
- The Company expects to launch SPN-830 in the fourth quarter of 2021, if approved by the FDA.
SPN-820 - Novel first-in-class activator of mTORC1
- Preclinical and development activities are ongoing, with the goal of initiating a Phase II clinical program in treatment-resistant depression by the end of 2021.
Research and development (R&D) expenses in the third quarter of 2020 were $16.8 million, essentially unchanged from $16.9 million in the same quarter last year.
Selling, general and administrative (SG&A) expenses in the third quarter of 2020 were $54.7 million, compared to $39.3 million in the same quarter last year. This increase was primarily due to costs associated with the new CNS portfolio of commercial products acquired from US WorldMeds (USWM Acquisition) in the second quarter of 2020 and our ongoing preparations for the potential launch of SPN-812.
Amortization expense of intangible assets in the third quarter of 2020 were $6.1 million, compared to $1.3 million in the same quarter last year. This increase results from the USWM Acquisition.
Operating Earnings and Earnings Per Share
Operating earnings (GAAP) in the third quarter of 2020 were $56.1 million, compared to $39.7 million in the third quarter of 2019. Net earnings (GAAP) in the third quarter of 2020 were $40.0 million, or $0.74 per diluted share, as compared to $28.9 million, or $0.54 per diluted share, in the same period last year.
Balance Sheet Highlights
As of September 30, 2020, the Company had $740.1 million in cash, cash equivalents, marketable securities and long term marketable securities, compared to $938.8 million at December 31, 2019. During the first nine months of 2020, the Company generated $107.5 million of cash from operations, inclusive of net changes in working capital. The Company made cash payments of approximately $300 million for acquisition of the CNS portfolio of US WorldMeds and $25 million paid to Navitor upon executing the development and option agreement for SPN-820.
The Company is revising full year 2020 financial guidance, which consists of the following components, inclusive of the impact of acquiring the CNS portfolio of US WorldMeds as of June 9, 2020:
|($ in millions)||Current (As of November 3, 2020)||Previous (As of August 18, 2020)|
|Net product sales||$500 - $525||$460 - $500|
|Research and development expense||Approximately $75||Approximately $85|
|Selling, general and administrative expense||$215 - $225||$240 - $250|
|Amortization of intangible assets||$16||$15|
|Operating earnings (GAAP)||$145 - $160, including amortization of intangible assets||$90 - $110, including amortization of intangible assets|
Conference Call Details
The Company will hold a conference call hosted by Jack Khattar, President and Chief Executive Officer and the executive management team to discuss these results at 9:00 a.m. Eastern Time, on Wednesday, November 4, 2020.
Please refer to the information below for conference call dial-in information and webcast registration. Callers should dial in approximately 10 minutes prior to the start of the call.
|Conference dial-in:||(877) 288-1043|
|International dial-in:||(970) 315-0267|
|Conference Call Name:||Supernus Pharmaceuticals Third Quarter 2020 Earnings Conference Call|
Following the live call, a replay will be available on the Company's website, www.supernus.com, under “Investor Relations”.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; apomorphine infusion pump for hypomobility in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.
All trademarks are the property of their respective owners.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
|September 30,||December 31,|
|Cash and cash equivalents||$||204,293||$||181,381|
|Accounts receivable, net||133,107||87,332|
|Prepaid expenses and other current assets||24,493||11,611|
|Total current assets||552,015||472,644|
|Long term marketable securities||388,185||591,773|
|Property and equipment, net||17,395||17,068|
|Operating lease assets||21,019||21,279|
|Finance lease asset||21,676||—|
|Intangible assets, net||402,265||24,840|
|Deferred income tax assets||—||32,063|
|Liabilities and stockholders’ equity|
|Accrued product returns and rebates||136,973||107,629|
|Accrued expenses and other current liabilities||56,289||34,305|
|Contingent consideration, current portion||82,900||—|
|Income taxes payable||—||2,443|
|Operating lease liabilities, current portion||3,741||2,825|
|Finance lease liability, current portion||3,612||—|
|Nonrecourse liability related to sale of future royalties, current portion||4,898||3,244|
|Total current liabilities||299,606||160,587|
|Convertible notes, net||357,521||345,170|
|Contingent consideration, long term||33,000||—|
|Nonrecourse liability related to sale of future royalties, long term||14,960||19,248|
|Operating lease liabilities, long term||29,522||30,440|
|Finance lease liability, long term||19,289||—|
|Deferred income tax liabilities||37,941||—|
|Common stock, $0.001 par value; 130,000,000 shares authorized; 52,670,121 and 52,533,348 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively||53||53|
|Additional paid-in capital||403,396||388,410|
|Accumulated other comprehensive earnings, net of tax||9,700||7,417|
|Total stockholders’ equity||708,879||595,428|
|Total liabilities and stockholders’ equity||$||1,510,022||$||1,160,282|
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Earnings
(in thousands, except share and per share data)
|Three Months ended
|Nine Months ended
|Net product sales||$||152,133||$||100,034||$||368,607||$||285,491|
|Costs and expenses|
|Cost of goods sold(a)||21,388||4,819||33,926||12,547|
|Research and development||16,839||16,943||58,023||49,307|
|Selling, general and administrative||54,660||39,343||144,377||118,782|
|Amortization of intangible assets||6,108||1,306||9,814||3,918|
|Total costs and expenses||98,995||62,411||246,140||184,554|
|Other income (expense)|
|Other income (expense), net||(603||)||(36||)||2,925||54|
|Total other expense||(3,429||)||(139||)||(1,745||)||(1,180||)|
|Earnings before income taxes||52,711||39,590||128,955||106,575|
|Income tax expense||12,714||10,730||32,773||26,648|
|Earnings per share|
|Weighted-average shares outstanding|
(a) Excludes amortization of acquired intangible assets
Jack A. Khattar, President and Chief Executive Officer
Jim Kelly, EVP & Chief Financial Officer
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767